Intrexon (XON) Lifted to Hold at Zacks Investment Research
Intrexon (NYSE:XON) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday.
According to Zacks, “Intrexon the company's expanding portfolio of technologies has enabled it to develop a robust pipeline of candidates targeting a broad range of diseases including cancer and others. We are also positive on Intrexon’s efforts to expand through acquisitions, exclusive channel collaborations (ECCs) and joint ventures. Additionally, it announced the formation of a wholly-owned subsidiary-Precigen, Inc. as part of its structural alternatives so that it can take better decisions of its health business.However, the company largely depends on ECCs and license, and collaboration deals for revenues. Any unfavorable outcome from the development of these might be a major setback and hurt the company’s prospects too. Furthermore, shares of the company have underperformed the Medical Services industry in a year’s time. Estimates have remained stable ahead of the Q4 earnings results.”
A number of other analysts have also recently weighed in on the stock. ValuEngine cut shares of Intrexon from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Northland Securities restated a “buy” rating and set a $21.00 target price on shares of Intrexon in a report on Friday, November 10th. Bank of America reduced their target price on shares of Intrexon from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, November 10th. Stifel Nicolaus raised their target price on shares of Intrexon from $39.00 to $57.00 and gave the stock a “buy” rating in a report on Friday, November 10th. Finally, Griffin Securities reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Intrexon in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. Intrexon has a consensus rating of “Hold” and an average price target of $38.50.
Intrexon (NYSE:XON) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.02. Intrexon had a negative net margin of 66.88% and a negative return on equity of 18.68%. research analysts expect that Intrexon will post -1.06 EPS for the current fiscal year.
In other news, CEO Randal J. Kirk acquired 1,000,000 shares of the firm’s stock in a transaction that occurred on Friday, January 19th. The stock was purchased at an average price of $12.50 per share, with a total value of $12,500,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 56.30% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Intrexon by 3.4% in the 2nd quarter. Vanguard Group Inc. now owns 4,433,879 shares of the biotechnology company’s stock worth $106,811,000 after purchasing an additional 147,517 shares during the period. First Trust Advisors LP boosted its stake in shares of Intrexon by 3.4% during the 3rd quarter. First Trust Advisors LP now owns 1,588,779 shares of the biotechnology company’s stock valued at $30,203,000 after buying an additional 51,691 shares during the period. Peregrine Capital Management LLC boosted its stake in shares of Intrexon by 25.3% during the 3rd quarter. Peregrine Capital Management LLC now owns 583,328 shares of the biotechnology company’s stock valued at $11,089,000 after buying an additional 117,605 shares during the period. Northern Trust Corp boosted its stake in shares of Intrexon by 2.4% during the 2nd quarter. Northern Trust Corp now owns 322,110 shares of the biotechnology company’s stock valued at $7,760,000 after buying an additional 7,589 shares during the period. Finally, Frontier Capital Management Co. LLC boosted its stake in shares of Intrexon by 139.0% during the 4th quarter. Frontier Capital Management Co. LLC now owns 276,284 shares of the biotechnology company’s stock valued at $3,183,000 after buying an additional 160,701 shares during the period. 77.46% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Intrexon (XON) Lifted to Hold at Zacks Investment Research” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://theolympiareport.com/2018/01/24/intrexon-xon-lifted-to-hold-at-zacks-investment-research.html.
Intrexon Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.